IL-1beta-targeted antibody approved for rare autoinflammatory disorders.
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002648:Child; D002986:Clinical Trials as Topic; D017277:Drug Approval; D016503:Drug Delivery Systems; D010505:Familial Mediterranean Fever / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D006801:Humans; D053583:Interleukin-1beta / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D053583:Interleukin-1beta; C541220:canakinumab